Pharvaris N.V. (PHVS) News
Follow Pharvaris N.V. (PHVS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 31 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
PHVS: Deucrictibant's strong efficacy and safety data support its launch as a leading oral HAE therapy
Deucrictibant demonstrated high efficacy and a favorable safety profile in severe HAE patients, positioning it as a differentiated oral therapy for both on-demand and prophylactic use. Launch preparations are advanced, w
NEWS | Sep 15, 2026, 01:14 PM UTC
L
PHVS: Deucrictibant shows injectable-like efficacy in HAE, with robust launch and global plans underway
Deucrictibant achieved high efficacy in severe HAE patients, with a strong safety profile and rapid onset. Launch preparations are advanced, targeting both on-demand and prophylactic markets, with global expansion under
NEWS | Sep 15, 2026, 12:43 PM UTC
L
Guggenheim raises Pharvaris price target to $44
EQUITY | Sep 10, 2026, 02:28 PM UTC
L
PHVS: Oral deucrictibant matches injectable efficacy in HAE, with broad label and strong commercial prospects
Deucrictibant demonstrated high efficacy in phase III HAE trials, matching injectable therapies and offering oral convenience. Safety profile aligns with existing treatments, and regulatory filing is planned for next yea
EQUITY | Sep 09, 2026, 09:40 PM UTC
L
Morgan Stanley raises Pharvaris price target to $62 from $46
Morgan Stanley raised its price target on Pharvaris to $62.00 per share from $46.00, according to Benzinga ratings actions sourced by TradingView News.
EQUITY | Sep 09, 2026, 05:41 PM UTC
L
Pharvaris price target raised to $65 by Leerink Partners
Leerink Partners raised its Pharvaris price target to $65.00 per share from $50.00 and maintained an Outperform rating, per TradingView News via Benzinga.
EQUITY | Sep 09, 2026, 04:16 PM UTC
L
Wells Fargo keeps Pharvaris at Overweight; price target raised
Wells Fargo maintained Pharvaris at Overweight and raised its price target to $65.00 per share from $55.00.
EQUITY | Sep 09, 2026, 02:32 PM UTC
L
PHVS maintained at Outperform by RBC Capital
RBC Capital maintained Pharvaris (PHVS) at Outperform.
EQUITY | Sep 09, 2026, 01:50 PM UTC
L
PHVS price target raised to $79 from $75
Citizens raised its PHVS price target to $79.00 a share from $75.00.
EQUITY | Sep 09, 2026, 01:18 PM UTC
L
PHVS kept at Outperform by Wedbush
Wedbush maintained Pharvaris as Outperform rating.
EQUITY | Sep 09, 2026, 12:24 PM UTC
M
Roivant and Pharvaris surge to record highs on positive trial results
Roivant Sciences (ROIV) and Pharvaris (PHVS) hit all-time highs after reporting positive results for experimental therapies across different trial phases. ROIV was up more than 20% and PHVS was up nearly 8%.
EQUITY | Sep 08, 2026, 05:54 PM UTC
L
HC Wainwright maintains Pharvaris $60 price target
HC Wainwright & Co. maintained its price target on Pharvaris at $60.00 per share, according to Benzinga ratings actions reported via TradingView News.
EQUITY | Sep 08, 2026, 04:02 PM UTC
M
PHVS jumps after positive topline HAE trial results
Pharvaris (PHVS) shares rose after the company disclosed positive topline data from a hereditary angioedema (HAE) trial. The stock gained 11% to $39.26 on Tuesday.
EQUITY | Sep 08, 2026, 03:51 PM UTC
M
PHVS deucrictibant XR cuts HAE attack rates 83% in CHAPTER-3
PHVS reports phase III CHAPTER-3 results for deucrictibant XR: 83% reduction in HAE attack rates versus placebo and nearly half of treated patients remained attack-free over 24 weeks. The drug was well-tolerated with qua
EQUITY | Sep 08, 2026, 03:07 PM UTC
M
PHVS deucrictibant XR cuts HAE attack rates by 83%
Phase III CHAPTER-3 results for deucrictibant XR in HAE show attack rates reduced 83% versus placebo, with nearly half of treated patients remaining attack-free over 24 weeks. Therapy was well-tolerated and improved qual
EQUITY | Sep 08, 2026, 01:57 PM UTC
L
Pharvaris price target maintained at $42 by Wedbush
Wedbush maintained its price target for Pharvaris at $42.00 per share by this Wednesday, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 01:30 PM UTC
H
PHVS Phase 3 CHAPTER-3: deucrictibant XR cuts HAE attacks 83%
PHVS says its Phase 3 CHAPTER-3 trial showed deucrictibant XR 40 mg once daily reduced hereditary angioedema attack rates by 83% versus placebo, with rapid onset, sustained effect, improved quality of life, and a favorab
EQUITY | Sep 08, 2026, 01:02 PM UTC
M
PHVS says oral drug met main goal in late-stage hereditary angioedema trial
Pharvaris said its experimental oral drug prevented swelling attacks in patients with hereditary angioedema, meeting the main goal of a late-stage trial. Shares were up over 25% in premarket trading.
EQUITY | Sep 08, 2026, 11:50 AM UTC
M
Pharvaris reports positive topline CHAPTER-3 data for deucrictibant XR
Pharvaris says its CHAPTER-3 pivotal study of deucrictibant XR for prophylaxis of hereditary angioedema (HAE) attacks produced positive topline data, per the company announcement.
EQUITY | Sep 08, 2026, 10:57 AM UTC
M
PHVS announces positive topline data from CHAPTER-3 study
Pharvaris says its CHAPTER-3 pivotal study of deucrictibant XR for prophylaxis of HAE attacks produced positive topline results.
EQUITY | Sep 08, 2026, 10:57 AM UTC
L
Pharvaris shares translational and clinical data at Bradykinin Symposium 2026
Pharvaris (PHVS) presented translational, nonclinical and clinical data at the Bradykinin Symposium 2026 in Zug, Switzerland.
EQUITY | Sep 03, 2026, 10:57 AM UTC
L
PHVS - Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
PHVS - Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
EQUITY | Sep 03, 2026, 10:50 AM UTC
L
Pharvaris Reports Q2 2026 Financial Results
Pharvaris reports second quarter 2026 financial results and provides business update
EARNINGS | Aug 12, 2026, 10:50 AM UTC
L
PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
EQUITY | Jul 28, 2026, 11:29 AM UTC
L
Pharvaris announces publication of review article on bradykinin
Pharvaris announces publication of review article on bradykinin
EQUITY | Jul 22, 2026, 10:53 AM UTC
L
IBM downgraded, Cava upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: Morgan Stanley upgraded Cava Group
EQUITY | Jul 15, 2026, 01:34 PM UTC
L
PHVS Initiated Overweight W/$55.00 PT at Wells Fargo
PHVS Initiated Overweight W/$55.00 PT at Wells Fargo
EQUITY | Jul 15, 2026, 11:47 AM UTC
L
PHVS new Overweight W/ $55 PT @ WELLS
PHVS new Overweight W/ $55 PT @ WELLS
EQUITY | Jul 15, 2026, 11:36 AM UTC
L
Sector Update: Healthcare Stocks Mixed Premarket Monday
() -- Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.3%. Novartis (NVS) stock was down more than 1% a
MNA | Jul 06, 2026, 01:18 PM UTC
L
Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target A
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to re
REGULATION | Jul 06, 2026, 10:53 AM UTC
L
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to tre
REGULATION | Jul 06, 2026, 10:50 AM UTC